- 2021-02-18 09:00:00
- 1910
近日，關于PD-L1/TGF-β雙特異抗體YM101的研究《The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1》發表于(yu)《Journal of Hematology & Oncology》（中科院(yuan)分區一區，IF: 11.059）期刊(kan)。此(ci)研究由(you)華中科技大學同(tong)(tong)濟(ji)醫(yi)學院(yuan)附屬(shu)同(tong)(tong)濟(ji)醫(yi)院(yuan)（以下簡(jian)稱武漢(han)同(tong)(tong)濟(ji)醫(yi)院(yuan)）腫瘤(liu)科吳孔明教授團隊和武漢(han)友芝(zhi)(zhi)友生物(wu)制(zhi)藥(yao)公(gong)司（以下簡(jian)稱友芝(zhi)(zhi)友生物(wu)）周鵬飛博士團隊共同(tong)(tong)合作完成。
PD-1/PD-L1免(mian)(mian)疫(yi)檢(jian)查點(dian)(dian)是(shi)腫(zhong)(zhong)瘤免(mian)(mian)疫(yi)逃逸重(zhong)要信號(hao)，對應(ying)靶(ba)點(dian)(dian)的單(dan)抗(kang)是(shi)腫(zhong)(zhong)瘤免(mian)(mian)疫(yi)治(zhi)療(liao)的里程(cheng)碑事(shi)件，但在總體(ti)(ti)病人中(zhong)有(you)效(xiao)率低。近期研(yan)(yan)究(jiu)提(ti)示腫(zhong)(zhong)瘤微(wei)環(huan)境中(zhong)高(gao)表(biao)達的TGF-β也是(shi)抑制(zhi)免(mian)(mian)疫(yi)的重(zhong)要因(yin)素，TGF-β和(he)PD-L1通路既相互獨立(li)又交互作用(yong)，共同促(cu)進免(mian)(mian)疫(yi)逃避。理論上聯合清除(chu)腫(zhong)(zhong)瘤微(wei)環(huan)境中(zhong)的TGF-β和(he)PD-L1可增加PD-1/PD-L1單(dan)抗(kang)治(zhi)療(liao)效(xiao)果(guo)，逆轉其耐(nai)藥性。基于友(you)芝友(you)生(sheng)物自主專利(li)CHECKBODY™技術(shu)平(ping)臺，研(yan)(yan)究(jiu)團(tuan)隊制(zhi)備了世界首個(ge)TGF-β/PD-L1雙特(te)異(yi)性抗(kang)體(ti)(ti)YM101。實驗結果(guo)顯示YM101具有(you)雙靶(ba)點(dian)(dian)高(gao)親和(he)力(li)，體(ti)(ti)內研(yan)(yan)究(jiu)進一步(bu)表(biao)明，通過糾(jiu)正抑制(zhi)性的腫(zhong)(zhong)瘤免(mian)(mian)疫(yi)微(wei)環(huan)境協同阻斷PD-1/PD-L1免(mian)(mian)疫(yi)檢(jian)查點(dian)(dian)，其抗(kang)腫(zhong)(zhong)瘤作用(yong)顯著(zhu)強于抗(kang)PD-L1單(dan)抗(kang)。本研(yan)(yan)究(jiu)結果(guo)將為雙特(te)異(yi)性抗(kang)體(ti)(ti)研(yan)(yan)發平(ping)臺提(ti)供(gong)科(ke)學(xue)支撐(cheng)，為臨床應(ying)用(yong)提(ti)供(gong)指導。
因為(wei)雙(shuang)(shuang)特異(yi)性(xing)抗體(ti)的(de)(de)諸多(duo)優勢，國(guo)(guo)內外各(ge)大(da)制藥公司(si)均(jun)在(zai)此領域紛紛布(bu)局。武漢友(you)(you)芝(zhi)友(you)(you)生(sheng)物制藥有限公司(si)通(tong)過多(duo)年(nian)(nian)的(de)(de)不(bu)懈(xie)努力，成功建(jian)立了(le)具有國(guo)(guo)際自主知識(shi)產權(quan)的(de)(de)YBODY®雙(shuang)(shuang)抗平(ping)臺，已(yi)獲多(duo)項國(guo)(guo)內外發明專利授(shou)權(quan)，并獲批國(guo)(guo)內前(qian)二的(de)(de)雙(shuang)(shuang)抗體(ti)臨床(chuang)申請。目(mu)前(qian)友(you)(you)芝(zhi)友(you)(you)生(sheng)物已(yi)有三(san)個(ge)藥物（M802，M701和(he)Y150）獲得中美臨床(chuang)批件，均(jun)基于YBODY®平(ping)臺構建(jian)。而基于CHECKBODY™平(ping)臺構建(jian)的(de)(de)雙(shuang)(shuang)抗體(ti)Y101D正在(zai)進行(xing)中美IND雙(shuang)(shuang)報，且于今年(nian)(nian)1月份獲得美國(guo)(guo)臨床(chuang)批準。
往期推薦
友芝友生物PD-L1/TGF-β雙特異性抗體新藥獲得美國FDA臨床試驗批準
